View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May 02, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1
Trading Symbol	SGMO
Entity Registrant Name	SANGAMO BIOSCIENCES INC
Entity Central Index Key	0001001233
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		70,492,496

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 33,009	$ 69,482
Marketable securities	154,572	139,518
Interest receivable	402	307
Accounts receivable	2,567	2,521
Prepaid expenses	588	754
Total current assets	191,138	212,582
Marketable securities, non-current	1,003
Property and equipment, net	3,176	2,916
Goodwill	1,585	1,585
Other assets	146	152
Total assets	197,048	217,235
Current liabilities:
Accounts payable and accrued liabilities	3,111	8,229
Accrued compensation and employee benefits	1,722	2,748
Deferred revenues	5,261	9,120
Total current liabilities	10,094	20,097
Deferred revenues, non-current	7,334	4,699
Build-to-suit lease obligation	213
Total liabilities	17,641	24,796
Commitments and contingencies
Stockholders' equity:
Common stock, $0.01 par value; 160,000,000 shares authorized, 70,400,036 and 70,354,608 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively	704	703
Additional paid-in capital	564,367	560,989
Accumulated deficit	(385,747)	(369,253)
Accumulated other comprehensive income	83
Total stockholders' equity	179,407	192,439
Total liabilities and stockholders' equity	$ 197,048	$ 217,235

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	160,000,000	160,000,000
Common stock, shares issued	70,400,036	70,354,608
Common stock, shares outstanding	70,400,036	70,354,608

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues:
Collaboration agreements	$ 3,711	$ 12,671
Research grants	231	820
Total revenues	3,942	13,491
Operating expenses:
Research and development	15,266	14,980
General and administrative	5,357	4,732
Total operating expenses	20,623	19,712
Loss from operations	(16,681)	(6,221)
Interest and other income, net	187	154
Loss before income taxes	(16,494)	(6,067)
Benefit from income taxes		748
Net loss	$ (16,494)	$ (5,319)
Basic and diluted net loss per share	$ (0.23)	$ (0.08)
Shares used in computing basic and diluted net loss per share	70,373	69,283

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (16,494)	$ (5,319)
Change in unrealized gain on available-for-sale securities, net	83	50
Comprehensive loss	$ (16,411)	$ (5,269)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Operating Activities:
Net loss	$ (16,494)	$ (5,319)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	245	147
Amortization of premium on marketable securities	72	241
Stock-based compensation	3,194	2,953
Change in fair value of contingent consideration liability		(1,800)
Intangible impairment		1,870
Benefit from income taxes		(748)
Net changes in operating assets and liabilities:
Interest receivable	(95)	25
Accounts receivable	(46)	3,730
Prepaid expenses and other assets	172	101
Accounts payable and accrued liabilities	(5,158)	(2,477)
Accrued compensation and employee benefits	(1,026)	(1,150)
Deferred revenues	(1,224)	34
Net cash used in operating activities	(20,360)	(2,393)
Investing Activities:
Purchases of marketable securities	(84,816)	(39,423)
Maturities of marketable securities	68,770	58,955
Purchases of property and equipment	(252)	(1,084)
Net cash provided by / (used in) investing activities	(16,298)	18,448
Financing Activities:
Taxes paid related to net share settlement of equity awards	(2)	(7)
Proceeds from issuance of common stock	187	3,178
Net cash provided by financing activities	185	3,171
Net increase / (decrease) in cash and cash equivalents	(36,473)	19,226
Cash and cash equivalents, beginning of period	69,482	6,030
Cash and cash equivalents, end of period	33,009	25,256
Supplemental disclosure of noncash investing activities:
Property and equipment included in accrued liabilities	$ 253	$ 579

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	NOTE 1—BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (“Sangamo” or the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The condensed consolidated balance sheet data at December 31, 2015 were derived from the audited consolidated financial statements included in Sangamo’s Form 10-K for the year ended December 31, 2015, as filed with the SEC. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December 31, 2015, included in Sangamo’s Form 10-K, as filed with the SEC. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the first quarter of 2016, we revised the estimated performance period of the upfront Biogen license through June 2019. This change increased net loss by $0.9 million and increased our basic net loss per share by $0.01 for the three month period ended March 31, 2016. Revenue Recognition Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee’s product sales. For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January 1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG (Shire), in January 2012 and Biogen Inc., formerly Biogen Idec Inc. (Biogen) in January 2014 were evaluated under these amended accounting standards. Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company’s performance. Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. Recent Accounting Standards In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Stock Compensation. The objective of this amendment is part of the FASB’s Simplification Initiative as it applies to several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2016-09 on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. ASU 2016-02 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Under ASU 2016-02, lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Lessees and lessors may not apply a full retrospective transition approach. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2016-02 on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting ASU 2014-15 on its consolidated financial statements is material. In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i) apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii) apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

Fair Value Measurement

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurement

NOTE 2—FAIR VALUE MEASUREMENT

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents, and available-for sale-securities. The fair value of these assets were determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

The fair value measurements of the Company’s cash equivalents, and available-for-sale marketable securities are identified at the following levels within the fair value hierarchy (in thousands):

	March 31, 2016
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	19,387	$	19,387	$	—	$	—
U.S. government sponsored entity debt securities		8,670		8,670		—		—
Total		28,057		28,057		—		—
Marketable securities:
Commercial paper securities		32,468		—		32,468		—
Corporate debt securities		14,559		—		14,559		—
U.S. government sponsored entity debt securities		108,548		—		108,548		—
Total		155,575		—		155,575		—
Total cash equivalents and marketable securities	$	183,632	$	28,057	$	155,575	$	—

	December 31, 2015
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	25,070	$	25,070	$	—	$	—
Commercial paper securities		2,000		2,000		—		—
U.S. government sponsored entity debt securities		38,867		38,867		—		—
Total		65,937		65,937		—		—
Marketable securities:
Commercial paper securities		30,717		—		30,717		—
Corporate debt securities		17,263		—		17,263		—
U.S. government sponsored entity debt securities		91,538		—		91,538		—
Total		139,518		—		139,518		—
Total cash equivalents and marketable securities	$	205,455	$	65,937	$	139,518	$	—

The Company generally classifies its marketable securities as Level 2. Instruments can be classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

3 Months Ended

Mar. 31, 2016

Investments Debt And Equity Securities [Abstract]

Marketable Securities

NOTE 3—MARKETABLE SECURITIES

Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of substantially identical assets. Unrealized holding gains and losses are included in accumulated other comprehensive income (loss). Investments that have maturities beyond one year as of the end of the reporting period are classified as non-current.

The Company’s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company’s cost basis, the financial condition and near-term prospects of the investee, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, which is determined using the specific identification method

The table below summarizes the Company’s investments (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		(Losses)			Fair Value
March 31, 2016
Cash equivalents:
Money market funds	$	19,387	$	—	$	—		$	19,387
U.S. government sponsored entity debt securities		8,669		1		—			8,670
Total		28,056		1		—			28,057
Available-for-sale securities:
Commercial paper securities	$	32,413	$	55	$	—		$	32,468
Corporate debt securities		14,563		1		(5	)		14,559
U.S. government sponsored entity debt securities		108,501		50		(3	)		108,548
Total		155,477		106		(8	)		155,575
Total cash equivalents and available-for-sale securities	$	183,533	$	107	$	(8	)	$	183,632
December 31, 2015
Cash equivalents:
Money market funds	$	25,070	$	—	$	—		$	25,070
Commercial paper securities		2,000		—		—			2,000
U.S. government sponsored entity debt securities		38,866		1		—			38,867
Total		65,936		1		—			65,937
Available-for-sale securities:
Commercial paper securities	$	30,667	$	50	$	—		$	30,717
Corporate debt securities		17,275		—		(12	)		17,263
U.S. government sponsored entity debt securities		91,562		—		(24	)		91,538
Total		139,504		50		(36	)		139,518
Total cash equivalents and available-for-sale securities	$	205,440	$	51	$	(36	)	$	205,455

The Company had no other-than-temporary impairments of its investments for the three months ended March 31, 2016 or the twelve months ended December 31, 2015. As of March 31, 2016 and December 31, 2015, all of the Company’s investments had maturity dates within two years. The Company had no material realized losses or other-than-temporary impairments of available-for-sale securities. Sangamo has the intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. No investments were other-than-temporarily impaired.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Basic and Diluted Net Loss Per Share	3 Months Ended
Basic and Diluted Net Loss Per Share	Mar. 31, 2016
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	NOTE 4—BASIC AND DILUTED NET LOSS PER SHARE Basic net loss per share has been computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period. Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of stock options and restricted stock units, which are all anti-dilutive. The total number of shares subject to stock options and restricted stock units outstanding were excluded from consideration in the calculation of diluted net loss per share. Stock options and restricted stock units outstanding for the three months ended March 31, 2016 and 2015 were 8,880,007 and 8,522,752, respectively.

Major Customers, Partnerships and Strategic Alliances

3 Months Ended

Mar. 31, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Major Customers, Partnerships and Strategic Alliances

NOTE 5—MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES

Collaboration Agreements

Collaboration and License Agreement with Biogen Inc. in Human Therapeutics

In January 2014 the Company entered into a Global Research, Development and Commercialization Collaboration and License Agreement (the “Biogen Agreement”) with Biogen, pursuant to which Sangamo and Biogen collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo’s zinc finger DNA-binding protein (ZFP) technology for hemoglobinopathies, including beta-thalassemia and sickle cell disease (SCD).

Under the Biogen Agreement, Sangamo and Biogen jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first ZFP Therapeutic developed under the Biogen Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (IND) application for ZFP Therapeutics intended to treat SCD. For both programs, Biogen is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Biogen Agreement. At the end of specified research terms for each program or under certain specified circumstances, Biogen retains the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any licensed product to treat beta-thalassemia and SCD developed under the Biogen Agreement, and Biogen agrees to compensate Sangamo for such co-promotion activities.

In January 2016 Sangamo and Biogen agreed on an updated beta-thalassemia Development Plan and budget using the BCL11A Enhancer target. As a result of this change, we updated the estimated performance period of the upfront license through June 2019. We also updated the milestones to be received based on the updated performance period of our deliverables under the Biogen Agreement. Sangamo received an upfront license fee of $20.0 million upon entering into the Biogen Agreement. In addition, the Company will also be eligible to receive up to $126.3 million in payments upon the achievement of specified research, regulatory, clinical development milestones, as well as up to $167.5 million in payments upon the achievement of specified commercialization and sales milestones. In addition, if products are commercialized under the Biogen Agreement, Biogen will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Biogen Agreement.

All contingent payments under the Biogen Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Biogen Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i) that can be achieved based in whole or in part on either the Company’s performance or on the occurrence of a specific outcome resulting from the Company’s performance, (ii) for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii) that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Biogen Agreement, assuming all other applicable revenue recognition criteria have been met.

Subject to the terms of the Biogen Agreement, Sangamo grants Biogen an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Biogen Agreement. Sangamo also grants Biogen a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, of Sangamo’s interest in certain other intellectual property developed pursuant to the Biogen Agreement.

The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Biogen apart from the research services to be performed pursuant to the Biogen Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis through June 2019, which is the estimated term during which the Company will perform research services. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect our current assumptions regarding the timing of our deliverables. As of March 31, 2016, the Company has deferred revenue of $8.0 million related to the Biogen Agreement.

Revenues recognized under the agreement with Biogen for the three months ended March 31, 2016 and 2015 were as follows (in thousands):

	Three months ended
	March 31,
	2016		2015
Revenue related to Biogen Collaboration:
Recognition of upfront fee	$	608	$	1,523
Research services		2,031		1,533
Total	$	2,639	$	3,056

Related costs and expenses incurred under the Biogen Agreement related to the beta-thalassemia project, which was co-funded with California Institute for Regenerative Medicine (CIRM), were $2.0 million and $1.4 million during the three months ended March 31, 2016 and 2015, respectively. Related costs and expenses for other projects including sickle cell disease under the Biogen agreement were $0.1 million and $1.1 million during the three months ended March 31, 2016 and 2015, respectively.

Amended Collaboration and License Agreement with Shire International GmbH in Human Therapeutics and Diagnostics

In January 2012 the Company entered into a collaboration and license agreement (the “Shire Agreement”) with Shire, pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo’s novel ZFP technology. This agreement was amended on September 1, 2015.

Under the original Shire Agreement, the Company and Shire agreed to develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets will be used for treating or diagnosing hemophilia A and B. In June 2012, Shire selected a fifth gene target for the development of a ZFP Therapeutic for Huntington’s disease. Shire had the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo’s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets.

Under the terms of the Shire Agreement, the Company was responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire was responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimbursed Sangamo for agreed upon internal and external program-related research costs. The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement in 2012. In 2014 Sangamo recognized a $1.0 million milestone payment related to the hemophilia program.

On September 1, 2015, the Shire Agreement was amended such that Shire agreed to return to Sangamo the exclusive, world-wide rights to gene targets for the development and commercialization of ZFP Therapeutics for hemophilia A and B. Shire retains the rights and will continue to develop a ZFP Therapeutic for Huntington’s disease and a ZFP Therapeutic for one additional gene target yet to be named. Sangamo will provide certain target feasibility services, and upon Shire’s request, certain research activities according to a research plan as agreed upon by both companies. Such research activities performed by Sangamo will be reimbursed by Shire. Shire’s rights with respect to other targets contemplated in the original agreement revert to Sangamo. Under the revised agreement, each company is responsible for expenses associated with its own programs and will reimburse the other for any ongoing services provided. Shire is responsible for reimbursement of $4.0 million related to obligations prior to the amendment date which is being recognized in revenue as expenses are incurred. During the three months ended March 31, 2016, there were no expenses incurred and recognized related to prior obligations. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs. Under the amended agreement, Shire does not have any milestone payment obligations to us with respect to the retained programs, but it is required to pay single digit percentage royalties to us, up to a specified maximum cap, on the commercial sales of ZFP therapeutic products from such programs. Under the Agreement, Sangamo has full control over, and full responsibility for the costs of, the hemophilia programs returned to us, subject to certain diligence obligations and Shire’s right of first negotiation to obtain a license to such programs under certain circumstances. The Company is required to pay single digit percentage royalties to Shire, up to a specified maximum cap, on commercial sales of ZFP therapeutic products from such returned programs.

The Company has identified the deliverables within the amended arrangement as a license to the technology and on-going research services activities. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire amendment. Sangamo continues to be responsible for research activities related to our licensed technology with Shire under the amendment. As a result, the Company will continue to recognize revenue from the upfront payment received upon entering into the original Shire agreement in 2012 on a straight-line basis over the six-year initial research term during which the Company expects to perform research services. As of March 31, 2016, the Company has deferred revenue of $4.0 million related to the Shire Agreement.

Revenues recognized under the agreement with Shire for the three months ended March 31, 2016 and 2015 were as follows (in thousands):

	Three months ended
	March 31,
	2016		2015
Revenue related to Shire Collaboration:
Recognition of upfront fee	$	542	$	542
Research services		429		4,522
Total	$	971	$	5,064

Related costs and expenses incurred under the Shire agreement were $0.4 million and $4.5 million during the three months ended March 31, 2016 and 2015, respectively.

Agreement with Sigma-Aldrich Corporation in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering

In July 2007 the Company entered into a license agreement (the “Sigma Agreement”) with Sigma-Aldrich Corporation (Sigma). Under the Sigma Agreement, Sangamo agreed to provide Sigma with access to Sangamo’s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (DAS). Under the Sigma Agreement, Sangamo and Sigma agreed to conduct a three-year research program to develop laboratory research reagents using Sangamo’s ZFP technology during which time Sangamo agreed to assist Sigma in connection with its efforts to market and sell services employing the Company’s ZFP technology in the research field. Sangamo has transferred its ZFP manufacturing technology to Sigma.

In October 2009 the Company expanded the Sigma Agreement. In addition to the original terms of the Sigma Agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. Sangamo has received commercial license fees of $5.0 million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million.

Revenues recognized under the agreement with Sigma for the three months ended March 31, 2016 and 2015 were as follows (in thousands):

	Three months ended
	March 31,
	2016		2015
Revenue related to Sigma Collaboration:
Royalty revenues	$	12	$	264
License fee revenues		7		4,256
Total	$	19	$	4,520

Related costs and expenses incurred under the Sigma agreement were $0.0 million and $0.2 million during the three months ended March 31, 2016 and 2015, respectively.

Agreement with Dow AgroSciences in Plant Agriculture

In October 2005 the Company entered into an exclusive commercial license agreement with Dow AgroSciences, LLC (DAS). Under this agreement, Sangamo provides DAS with access to proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP transcription factors (ZFP TFs) or ZFP nucleases (ZFNs) into humans or animals for diagnostic, therapeutic or prophylactic purposes. The Company’s agreement with DAS provided for an initial three year research term. In June 2008, DAS exercised its option under the agreement to obtain a commercial license to sell products incorporating or derived from plant cells generated using the Company’s ZFP technology, including agricultural crops, industrial products and plant-derived biopharmaceuticals. The exercise of the option triggered a one-time commercial license fee of $6.0 million, payment of the remaining $2.3 million of the previously agreed $4.0 million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo’s ZFP technology to third parties for use in plant cells, plants or plant cell cultures and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December 31, 2012.

The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the Agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years. The Company does not have any ongoing performance obligations with respect to the sublicensing activities to be conducted by DAS. DAS has the right to terminate the agreement at any time; accordingly, the Company’s actual sublicense fees over the term of the agreement could be lower than $25.3 million. In addition, each party may terminate the agreement upon an uncured material breach by the other party. In the event of any termination of the agreement, all rights to use the Company’s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo’s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company’s ZFP technology.

There were no revenues or related costs and expenses incurred under the agreement during the three months ended March 31, 2016 and 2015, respectively.

Funding from Research Foundations

California Institute for Regenerative Medicine - HIV

In May 2014 CIRM agreed to fund a $5.6 million Strategic Partnership Award to fund the clinical studies of this potentially curative ZFP Therapeutic for HIV/AIDS based on the application of its ZFN genome editing technology in hematopoietic stem and progenitor cells (HSPCs). The four year grant provides matching funds to support evaluation of the Company’s stem cell-based ZFP Therapeutic in a clinical trial in HIV-infected individuals conducted at City of Hope.

There were no revenues attributable to research and development performed under the Strategic Partnership Award during the three months ended March 31, 2016 and 2015, respectively. Related costs and expenses incurred under the CIRM Strategic Partnership Award were $0.3 million and $0.3 million during the three months ended March 31, 2016 and 2015, respectively.

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 6—INCOME TAXES The Company maintains deferred tax assets that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. These deferred tax assets include net operating loss carryforwards, research credits and capitalized research and development costs. Realization of deferred tax assets is dependent upon future earnings, if any, the timing and amount of which are uncertain based on Sangamo’s history of losses. Accordingly, the Company’s net deferred tax assets have been fully offset by a valuation allowance. Utilization of operating losses and credits may be subject to substantial annual limitation due to ownership change provisions of the Internal Revenue Code of 1986, as amended and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.

Stock-Based Compensation

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

NOTE 7—STOCK-BASED COMPENSATION

The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 (in thousands):

	Three months ended
	March 31,
	2016		2015
Research and development	$	1,850	$	1,691
General and administrative		1,344		1,262
Total stock-based compensation expense	$	3,194	$	2,953

Build-to-Suit Lease	3 Months Ended
Build-to-Suit Lease	Mar. 31, 2016
Leases Operating [Abstract]
Build-to-Suit Lease	NOTE 8—BUILD-TO-SUIT LEASE In December 2015 the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 41,400 square feet of space, in Richmond, California. The lease agreement expires five years after substantial completion of the building, which is estimated to be completed in late 2016. The Company has two options to extend the lease term for up to a combined additional ten years. The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner. In connection with the Company’s accounting for this transaction, the Company will capitalize costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. As of the three months ended March 31, 2016, $0.2 million of costs were capitalized in construction in progress with a corresponding build-to-suit lease obligation recognized related to this lease. Upon construction a portion of the monthly lease payment will be allocated to land rent and recorded as an operating lease expense and the non-interest portion of the amortized lease payments to the landlord related to the rent of the building will be applied to reduce the build-to-suit lease obligation.

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Sangamo BioSciences, Inc. (“Sangamo” or the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending December 31, 2016. The condensed consolidated balance sheet data at December 31, 2015 were derived from the audited consolidated financial statements included in Sangamo’s Form 10-K for the year ended December 31, 2015, as filed with the SEC. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and footnotes thereto for the year ended December 31, 2015, included in Sangamo’s Form 10-K, as filed with the SEC.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the first quarter of 2016, we revised the estimated performance period of the upfront Biogen license through June 2019. This change increased net loss by $0.9 million and increased our basic net loss per share by $0.01 for the three month period ended March 31, 2016.
Revenue Recognition	Revenue Recognition Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee’s product sales. For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January 1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG (Shire), in January 2012 and Biogen Inc., formerly Biogen Idec Inc. (Biogen) in January 2014 were evaluated under these amended accounting standards. Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that the objectives will be achieved and if the achievement is based on the Company’s performance. Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which have not been earned. Sangamo’s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred.
Recent Accounting Standards	Recent Accounting Standards In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Stock Compensation. The objective of this amendment is part of the FASB’s Simplification Initiative as it applies to several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The guidance is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2016-09 on its consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases. Under the new guidance, lessees will be required to recognize a lease liability and a right-of-use asset for all leases (with the exception of short-term leases) at the commencement date. ASU 2016-02 is effective for annual and interim periods beginning on or after December 15, 2018 and early adoption is permitted. Under ASU 2016-02, lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Lessees and lessors may not apply a full retrospective transition approach. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2016-02 on its consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. In doing so, companies will have reduced diversity in the timing and content of footnote disclosures than under the current guidance. ASU 2014-15 is effective for the Company in the first quarter of 2016 with early adoption permitted. The Company does not believe the impact of adopting ASU 2014-15 on its consolidated financial statements is material. In May 2014 the FASB issued ASU 2014-09, Revenue from Contracts with Customers (ASU 2014-09). This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i) apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii) apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company is currently in the process of evaluating the impact of the pending adoption of ASU 2014-09 on its consolidated financial statements.

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Fair Value Measurement (Tables)

3 Months Ended

Mar. 31, 2016

Fair Value Disclosures [Abstract]

Summary of Fair Value Measurements of Cash Equivalents, and Available-for-Sale Marketable Securities

The fair value measurements of the Company’s cash equivalents, and available-for-sale marketable securities are identified at the following levels within the fair value hierarchy (in thousands):

	March 31, 2016
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	19,387	$	19,387	$	—	$	—
U.S. government sponsored entity debt securities		8,670		8,670		—		—
Total		28,057		28,057		—		—
Marketable securities:
Commercial paper securities		32,468		—		32,468		—
Corporate debt securities		14,559		—		14,559		—
U.S. government sponsored entity debt securities		108,548		—		108,548		—
Total		155,575		—		155,575		—
Total cash equivalents and marketable securities	$	183,632	$	28,057	$	155,575	$	—

	December 31, 2015
	Fair Value Measurements
	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	25,070	$	25,070	$	—	$	—
Commercial paper securities		2,000		2,000		—		—
U.S. government sponsored entity debt securities		38,867		38,867		—		—
Total		65,937		65,937		—		—
Marketable securities:
Commercial paper securities		30,717		—		30,717		—
Corporate debt securities		17,263		—		17,263		—
U.S. government sponsored entity debt securities		91,538		—		91,538		—
Total		139,518		—		139,518		—
Total cash equivalents and marketable securities	$	205,455	$	65,937	$	139,518	$	—

Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2016

Investments Debt And Equity Securities [Abstract]

Schedule of Investments

The table below summarizes the Company’s investments (in thousands):

			Gross		Gross
	Amortized		Unrealized		Unrealized			Estimated
	Cost		Gains		(Losses)			Fair Value
March 31, 2016
Cash equivalents:
Money market funds	$	19,387	$	—	$	—		$	19,387
U.S. government sponsored entity debt securities		8,669		1		—			8,670
Total		28,056		1		—			28,057
Available-for-sale securities:
Commercial paper securities	$	32,413	$	55	$	—		$	32,468
Corporate debt securities		14,563		1		(5	)		14,559
U.S. government sponsored entity debt securities		108,501		50		(3	)		108,548
Total		155,477		106		(8	)		155,575
Total cash equivalents and available-for-sale securities	$	183,533	$	107	$	(8	)	$	183,632
December 31, 2015
Cash equivalents:
Money market funds	$	25,070	$	—	$	—		$	25,070
Commercial paper securities		2,000		—		—			2,000
U.S. government sponsored entity debt securities		38,866		1		—			38,867
Total		65,936		1		—			65,937
Available-for-sale securities:
Commercial paper securities	$	30,667	$	50	$	—		$	30,717
Corporate debt securities		17,275		—		(12	)		17,263
U.S. government sponsored entity debt securities		91,562		—		(24	)		91,538
Total		139,504		50		(36	)		139,518
Total cash equivalents and available-for-sale securities	$	205,440	$	51	$	(36	)	$	205,455

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Major Customers, Partnerships and Strategic Alliances (Tables)

3 Months Ended

Mar. 31, 2016

Biogen Inc [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement with Biogen for the three months ended March 31, 2016 and 2015 were as follows (in thousands):

	Three months ended
	March 31,
	2016		2015
Revenue related to Biogen Collaboration:
Recognition of upfront fee	$	608	$	1,523
Research services		2,031		1,533
Total	$	2,639	$	3,056

Shire AG [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement with Shire for the three months ended March 31, 2016 and 2015 were as follows (in thousands):

	Three months ended
	March 31,
	2016		2015
Revenue related to Shire Collaboration:
Recognition of upfront fee	$	542	$	542
Research services		429		4,522
Total	$	971	$	5,064

Sigma-Aldrich Corporation [Member]

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues Recognized under Agreement

Revenues recognized under the agreement with Sigma for the three months ended March 31, 2016 and 2015 were as follows (in thousands):

	Three months ended
	March 31,
	2016		2015
Revenue related to Sigma Collaboration:
Royalty revenues	$	12	$	264
License fee revenues		7		4,256
Total	$	19	$	4,520

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2016

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expense

The following table shows total stock-based compensation expense included in the condensed consolidated statements of operations for the three months ended March 31, 2016 and 2015 (in thousands):

	Three months ended
	March 31,
	2016		2015
Research and development	$	1,850	$	1,691
General and administrative		1,344		1,262
Total stock-based compensation expense	$	3,194	$	2,953

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail) - Biogen Inc [Member] - Change in estimated performance period [Member] $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($) $ / shares
Change In Accounting Estimate [Line Items]
Increase in net loss \| $	$ 0.9
Increase in basic net loss per share \| $ / shares	$ 0.01

Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, and Available-for-Sale Marketable Securities (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	$ 28,057	$ 65,937
Total marketable securities	155,575	139,518
Total cash equivalents and marketable securities	183,632	205,455
Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	19,387	25,070
Commercial paper securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents		2,000
Total marketable securities	32,468	30,717
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	28,057	65,937
Total cash equivalents and marketable securities	28,057	65,937
Level 1 [Member] \| Money market funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	19,387	25,070
Level 1 [Member] \| Commercial paper securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents		2,000
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	155,575	139,518
Total cash equivalents and marketable securities	155,575	139,518
Level 2 [Member] \| Commercial paper securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	32,468	30,717
U.S. government sponsored entity debt securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	8,670	38,867
Total marketable securities	108,548	91,538
U.S. government sponsored entity debt securities [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total cash equivalents	8,670	38,867
U.S. government sponsored entity debt securities [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	108,548	91,538
Corporate debt securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	14,559	17,263
Corporate debt securities [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total marketable securities	$ 14,559	$ 17,263

Marketable Securities - Schedule of Investments (Detail) - USD ($) $ in Thousands	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	$ 33,009	$ 69,482	$ 25,256	$ 6,030
Total cash equivalents	28,057	65,937
Amortized Cost	183,533	205,440
Gross Unrealized Gains	107	51
Gross Unrealized (Losses)	(8)	(36)
Estimated Fair Value	183,632	205,455
Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	155,477	139,504
Gross Unrealized Gains	106	50
Gross Unrealized (Losses)	(8)	(36)
Estimated Fair Value	155,575	139,518
Money market funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	19,387	25,070
Total cash equivalents	19,387	25,070
Cash equivalents [Member]
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	28,056	65,936
Gross Unrealized Gains	1	1
Total cash equivalents	28,057	65,937
Commercial paper securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents		2,000
Total cash equivalents		2,000
Commercial paper securities [Member] \| Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	32,413	30,667
Gross Unrealized Gains	55	50
Estimated Fair Value	32,468	30,717
U.S. government sponsored entity debt securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Cash and cash equivalents	8,669	38,866
Gross Unrealized Gains	1	1
Total cash equivalents	8,670	38,867
U.S. government sponsored entity debt securities [Member] \| Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	108,501	91,562
Gross Unrealized Gains	50
Gross Unrealized (Losses)	(3)	(24)
Estimated Fair Value	108,548	91,538
Corporate debt securities [Member] \| Available-for-sale securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	14,563	17,275
Gross Unrealized Gains	1
Gross Unrealized (Losses)	(5)	(12)
Estimated Fair Value	$ 14,559	$ 17,263

Marketable Securities - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Investments Debt And Equity Securities [Abstract]
Investments other-than-temporarily impaired	$ 0	$ 0
Investments maturity period	2 years	2 years
Realized losses	$ 0
Other-than-temporary impairments of available-for-sale securities	$ 0

Basic and Diluted Net Loss Per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock options and restricted stock units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Stock options and restricted stock units outstanding	8,880,007	8,522,752

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)	1 Months Ended				3 Months Ended		12 Months Ended
	Jan. 31, 2016 USD ($)	Jan. 31, 2014 USD ($) Program	Jun. 30, 2012 Targets	Jan. 31, 2012 USD ($) Targets	Mar. 31, 2016 USD ($) Product Targets	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 01, 2015 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of research programs \| Program		2
Research and development					$ 15,266,000	$ 14,980,000
Biogen Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement		$ 20,000,000
Milestone payments received					$ 0
Number of products approved \| Product					0
Royalty revenues					$ 0
Deferred revenue					8,000,000
Biogen Inc [Member] \| Beta-thalassemia Project [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development					2,000,000	1,400,000
Biogen Inc [Member] \| Other Projects [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development					100,000	1,100,000
Biogen Inc [Member] \| Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential amount eligible to receive for certain milestones	$ 126,300,000
Potential amount to be funded for achievement of specified commercialized and sales milestones	$ 167,500,000
Shire AG [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement				$ 13,000,000
Deferred revenue					4,000,000
Research and development					$ 400,000	$ 4,500,000
Aggregate number of gene targets \| Targets				7
Number of initial gene targets \| Targets				4
Number of gene targets \| Targets			5
Number of additional gene targets \| Targets			2		1
Recognition of milestone							$ 1,000,000
Amount of obligation related to reimbursement								$ 4,000,000
Revenue recognized related to prior obligations					$ 0
Research program to develop laboratory research reagents					6 years

Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Biogen Inc [Member]
Revenues:
Recognition of upfront fee	$ 608,000	$ 1,523,000
Royalty revenues	0
Research services	2,031,000	1,533,000
Total	2,639,000	3,056,000
Shire AG [Member]
Revenues:
Recognition of upfront fee	542,000	542,000
Research services	429,000	4,522,000
Total	971,000	5,064,000
Sigma-Aldrich Corporation [Member]
Revenues:
Royalty revenues	12,000	264,000
License fee revenues	7,000	4,256,000
Total	$ 19,000	$ 4,520,000

Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended
	Oct. 31, 2009	Jul. 31, 2007	Mar. 31, 2016	Mar. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and development			$ 15,266	$ 14,980
Sigma-Aldrich Corporation [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research program to develop laboratory research reagents		3 years
Upfront license fee	$ 20,000
Public offering, common stock shares issued	636,133
Reduced royalty rate	10.50%
Funding available under the amended agreement	$ 25,000
Sigma-Aldrich Corporation [Member] \| Upfront license fee [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Upfront license fee	15,100
Common stock issued under license agreement	$ 4,900
Sigma-Aldrich Corporation [Member] \| License agreement terms [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement			5,000
Research and development			$ 0	$ 200

Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail) - Dow Agro Sciences [Member] - License agreement terms [Member] - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2005	Mar. 31, 2016	Mar. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research program to develop laboratory research reagents	3 years
One-time license fee earned on exercise of option	$ 6,000,000
Royalty revenues	$ 2,300,000
Percentage of royalties to be received from sublicensing	25.00%
Previously agreed research, development and commercialization milestone payments, and royalties on sales of products	$ 4,000,000
Fee due	$ 25,300,000
Minimum license annual fees specific reckoning period	11 years
Collaboration agreement related costs and expenses		$ 0	$ 0
Revenue attributable to research and development		$ 0	$ 0
Minimum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Annual fees	$ 250,000
Maximum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Annual fees	$ 3,000,000

Major Customers, Partnerships and Strategic Alliances - California Institute for Regenerative Medicine - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	May 31, 2014	Mar. 31, 2016	Mar. 31, 2015
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research grants		$ 231,000	$ 820,000
California Institute for Regenerative Medicine [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Funds due under the agreement	$ 5,600,000
Agreement to receive	4 years
Research grants		0	0
Collaboration agreement related costs and expenses		$ 300,000	$ 300,000

Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 3,194	$ 2,953
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	1,850	1,691
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 1,344	$ 1,262

Build-to-Suit Lease - Additional Information (Detail) $ in Millions	1 Months Ended
	Dec. 31, 2015 ft² Option	Mar. 31, 2016 USD ($)
Operating Leased Assets [Line Items]
Property leased \| ft²	41,400
Operating lease expiration period	5 years
Number of lease term extension options \| Option	2
Costs capitalized \| $		$ 0.2
Maximum [Member]
Operating Leased Assets [Line Items]
Lease agreement, extendable lease term	10 years